Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 1
1960 1
1961 5
1963 2
1964 1
1965 2
1966 2
1968 3
1969 5
1970 7
1971 5
1972 2
1973 3
1974 8
1975 7
1976 3
1977 13
1978 12
1979 5
1980 6
1981 9
1982 12
1983 14
1984 19
1985 15
1986 34
1987 25
1988 22
1989 38
1990 42
1991 39
1992 21
1993 26
1994 28
1995 29
1996 39
1997 36
1998 39
1999 38
2000 49
2001 50
2002 62
2003 70
2004 78
2005 85
2006 68
2007 75
2008 77
2009 78
2010 70
2011 78
2012 88
2013 98
2014 93
2015 94
2016 95
2017 110
2018 85
2019 90
2020 87
2021 43
Text availability
Article attribute
Article type
Publication date

Search Results

2,162 results
Results by year
Filters applied: . Clear all
Page 1
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. Taniguchi H, et al. Among authors: yano s. Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0. Nat Commun. 2019. PMID: 30651547 Free PMC article.
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Wang R, et al. Among authors: yano s. Nat Commun. 2020 Sep 14;11(1):4607. doi: 10.1038/s41467-020-18442-4. Nat Commun. 2020. PMID: 32929081 Free PMC article.
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. Okura N, et al. Among authors: yano s. Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17. Clin Cancer Res. 2020. PMID: 31953310
Melatonin is a potential drug for the prevention of bone loss during space flight.
Ikegame M, Hattori A, Tabata MJ, Kitamura KI, Tabuchi Y, Furusawa Y, Maruyama Y, Yamamoto T, Sekiguchi T, Matsuoka R, Hanmoto T, Ikari T, Endo M, Omori K, Nakano M, Yashima S, Ejiri S, Taya T, Nakashima H, Shimizu N, Nakamura M, Kondo T, Hayakawa K, Takasaki I, Kaminishi A, Akatsuka R, Sasayama Y, Nishiuchi T, Nara M, Iseki H, Chowdhury VS, Wada S, Ijiri K, Takeuchi T, Suzuki T, Ando H, Matsuda K, Somei M, Mishima H, Mikuni-Takagaki Y, Funahashi H, Takahashi A, Watanabe Y, Maeda M, Uchida H, Hayashi A, Kambegawa A, Seki A, Yano S, Shimazu T, Suzuki H, Hirayama J, Suzuki N. Ikegame M, et al. Among authors: yano s. J Pineal Res. 2019 Oct;67(3):e12594. doi: 10.1111/jpi.12594. Epub 2019 Jul 19. J Pineal Res. 2019. PMID: 31286565 Free PMC article.
SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals.
Ng BG, Sosicka P, Agadi S, Almannai M, Bacino CA, Barone R, Botto LD, Burton JE, Carlston C, Chung BH, Cohen JS, Coman D, Dipple KM, Dorrani N, Dobyns WB, Elias AF, Epstein L, Gahl WA, Garozzo D, Hammer TB, Haven J, Héron D, Herzog M, Hoganson GE, Hunter JM, Jain M, Juusola J, Lakhani S, Lee H, Lee J, Lewis K, Longo N, Lourenço CM, Mak CCY, McKnight D, Mendelsohn BA, Mignot C, Mirzaa G, Mitchell W, Muhle H, Nelson SF, Olczak M, Palmer CGS, Partikian A, Patterson MC, Pierson TM, Quinonez SC, Regan BM, Ross ME, Guillen Sacoto MJ, Scaglia F, Scheffer IE, Segal D, Singhal NS, Striano P, Sturiale L, Symonds JD, Tang S, Vilain E, Willis M, Wolfe LA, Yang H, Yano S, Powis Z, Suchy SF, Rosenfeld JA, Edmondson AC, Grunewald S, Freeze HH. Ng BG, et al. Among authors: yano s. Hum Mutat. 2019 Jul;40(7):908-925. doi: 10.1002/humu.23731. Epub 2019 Apr 24. Hum Mutat. 2019. PMID: 30817854 Free PMC article.
In Reply.
Arai S, Yano S. Arai S, et al. Among authors: yano s. J Thorac Oncol. 2020 Jun;15(6):e93. doi: 10.1016/j.jtho.2020.03.010. J Thorac Oncol. 2020. PMID: 32471570 No abstract available.
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.
Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S. Fukuda K, et al. Among authors: yano s. Cancer Res. 2019 Apr 1;79(7):1658-1670. doi: 10.1158/0008-5472.CAN-18-2052. Epub 2019 Feb 8. Cancer Res. 2019. PMID: 30737231 Free article.
2,162 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page